Fact-checked by Grok 2 weeks ago

PKA

Protein kinase A (PKA), also known as cyclic AMP-dependent protein kinase, is a family of serine/threonine-specific enzymes that catalyze the transfer of phosphate groups from ATP to target proteins, thereby modulating their function in response to cellular levels of the second messenger cyclic AMP (cAMP).^[1] PKA plays a central role in transducing signals from hormones and neurotransmitters that elevate cAMP, such as those acting through G protein-coupled receptors, and is essential for regulating diverse physiological processes including metabolism, gene expression, cell growth, and ion channel activity.^[2] Structurally, PKA exists as an inactive holoenzyme composed of two regulatory (R) subunits and two catalytic (C) subunits, forming a tetramer that dissociates upon cAMP binding to the R subunits, releasing the active C subunits to phosphorylate substrates.^[1] The R subunits include two main types—RI and RII—each with α and β isoforms, while the C subunits have three isoforms (Cα, Cβ, Cγ), with Cα being the most ubiquitous and encoded by the PRKACA gene on chromosome 19p13.1.^[2] This organization allows for precise spatial and temporal control, often mediated by A-kinase anchoring proteins (AKAPs) that tether PKA to specific subcellular locations, such as membranes or the nucleus.^[1] Functionally, PKA targets a consensus sequence featuring arginine residues adjacent to serine or threonine phosphorylation sites, affecting enzymes like phosphorylase kinase in glycogen metabolism, transcription factors such as CREB for gene regulation, and ion channels including calcium and chloride channels for membrane excitability.^[1] Discovered in 1968 by Edmond Fischer and Edwin Krebs as part of their work on reversible protein phosphorylation—which earned them the 1992 Nobel Prize in Physiology or Medicine—PKA's dysregulation has been implicated in various diseases, including cardiac disorders, endocrine tumors like Cushing's syndrome, and certain cancers.^[2] Its broad influence underscores PKA's status as a cornerstone of cAMP-mediated signaling in eukaryotic cells.^[1]

Introduction

Definition and Nomenclature

Protein Kinase A (PKA), also known as cyclic AMP-dependent protein kinase, is a family of serine/threonine-specific protein kinases whose activity is regulated by the second messenger cyclic adenosine monophosphate (cAMP).^[3] In its inactive form, PKA exists as a heterotetrameric holoenzyme composed of two regulatory (R) subunits and two catalytic (C) subunits, which maintains the catalytic subunits in an inhibited state.^[2] Upon elevation of intracellular cAMP levels, typically triggered by G protein-coupled receptor activation, cAMP binds to the regulatory subunits, inducing a conformational change that dissociates the complex and releases the active monomeric catalytic subunits to phosphorylate downstream protein substrates.^[4] This mechanism positions PKA as a central mediator in cAMP signaling pathways, influencing diverse cellular processes such as metabolism, gene expression, and ion channel function.^[3] The nomenclature of PKA subunits adheres to the Human Genome Organisation (HUGO) Gene Nomenclature Committee standards, with genes prefixed by "PRKA" followed by descriptors for subunit type and isoform.^[2] The regulatory subunits are classified into two main types: Type I (RI) and Type II (RII), each with alpha (α) and beta (β) isoforms, encoded by PRKAR1A (RIα), PRKAR1B (RIβ), PRKAR2A (RIIα), and PRKAR2B (RIIβ), respectively.^[3] These isoforms differ in their tissue distribution, cAMP-binding affinities, and subcellular localization, with RI isoforms generally cytosolic and more readily activated by cAMP, while RII isoforms are often anchored to cellular structures via A-kinase anchoring proteins (AKAPs).^[4] The catalytic subunits include three main isoforms: Cα (encoded by PRKACA), Cβ (PRKACB), and Cγ (PRKACG), all sharing a conserved kinase domain but exhibiting tissue-specific expression patterns.^[3] For instance, PRKACA produces multiple splice variants, including the ubiquitous Cα1 isoform (351 amino acids) and the testis-specific Cα2 isoform, which differs in its N-terminal region and lacks myristoylation.^[2] Similarly, PRKACB yields several variants such as Cβ1 (ubiquitous), Cβ2 (lymphocyte-specific), and neural-enriched forms like Cβ3 and Cβ4, which feature extended N-terminal tails influencing localization and function.^[4] PRKACG is predominantly expressed in testis and sperm, contributing to sperm motility.^[3] Additional related genes include PRKX (X-linked) and PRKY (Y-linked pseudogene), though these are not core PKA components.^[3] This isoform diversity enables PKA to form distinct holoenzymes (e.g., PKA-Iα, PKA-IIβ) with specialized roles in cellular signaling.^[4]

Biological Significance

Protein kinase A (PKA), also known as cAMP-dependent protein kinase, serves as a primary effector of cyclic AMP (cAMP) signaling, translating extracellular signals into intracellular responses through serine/threonine phosphorylation of diverse substrates. This enzyme complex, comprising catalytic (C) and regulatory (R) subunits, dissociates upon cAMP binding to the R subunits, releasing active C subunits that phosphorylate targets involved in fundamental cellular processes. PKA's broad substrate specificity—exceeding 380 identified proteins—enables it to regulate metabolism, gene transcription, ion channel activity, and cytoskeletal dynamics, ensuring coordinated cellular adaptation to hormonal and environmental cues.^[5] In metabolic regulation, PKA plays a pivotal role in energy homeostasis by phosphorylating enzymes that control glycogenolysis, lipolysis, and gluconeogenesis. For instance, in hepatocytes and adipocytes, PKA activation promotes glycogen breakdown via phosphorylase kinase and inhibits glycogen synthase, facilitating rapid glucose mobilization during fasting or stress. Similarly, in adipose tissue, PKA stimulates hormone-sensitive lipase, enhancing lipid mobilization to support energy demands. These actions underscore PKA's integration into the fight-or-flight response, where adrenergic stimulation elevates cAMP levels to prioritize catabolic pathways over anabolic ones. Dysregulation of this metabolic control contributes to disorders like diabetes, where impaired PKA signaling disrupts insulin sensitivity and glucose uptake.^[2]^[6] PKA exerts profound influence on gene expression and cellular plasticity, particularly through phosphorylation of transcription factors such as CREB (cAMP response element-binding protein), which activates promoters responsive to neuronal activity or stress. In the brain, this pathway is essential for long-term potentiation (LTP) and memory consolidation; PKA-mediated CREB phosphorylation in hippocampal neurons promotes synaptic strengthening and the transcription of genes like BDNF, supporting learning and adaptive behaviors. Beyond the nervous system, PKA regulates cell proliferation and differentiation in various tissues, including cardiac myocytes where it phosphorylates phospholamban to enhance sarcoplasmic reticulum calcium uptake, optimizing contractility. Spatial confinement of PKA by A-kinase anchoring proteins (AKAPs) ensures precise localization, such as near L-type calcium channels in cardiomyocytes or ionotropic receptors in neurons, amplifying signal specificity.^[7]^[8] The biological significance of PKA extends to disease pathology, where aberrant activity drives oncogenesis, neurodegeneration, and cardiovascular dysfunction. In cancers like colorectal carcinoma and adrenal tumors (e.g., Cushing's syndrome via PRKACA mutations such as L206R), hyperactive PKA promotes uncontrolled proliferation and cortisol overproduction by deregulating CREB and cell cycle checkpoints. In the heart, PKA's role in excitation-contraction coupling is disrupted in heart failure, leading to defective calcium handling and reduced contractility. Furthermore, in neurodegenerative conditions like Parkinson's disease, diminished PKA signaling impairs dopamine-mediated responses and neuronal survival. These multifaceted roles highlight PKA as a therapeutic target, with inhibitors modulating its activity to mitigate pathological outcomes while preserving physiological functions.^[2]^[9]^[6]

History

Discovery

The discovery of protein kinase A (PKA), also known as cAMP-dependent protein kinase, emerged from efforts to elucidate the mechanisms of hormonal regulation of glycogen metabolism in the mid-20th century. In 1955, Edmond H. Fischer and Edwin G. Krebs identified phosphorylase kinase as the enzyme responsible for phosphorylating glycogen phosphorylase b to its active form a, establishing the first example of reversible protein phosphorylation as a regulatory mechanism.^[10] This finding built on earlier work showing that hormones like epinephrine and glucagon stimulate glycogen breakdown, but the link to intracellular signaling remained unclear. Concurrently, Earl W. Sutherland discovered cyclic adenosine monophosphate (cAMP) in 1958 as a key second messenger formed in response to these hormones, mediating their effects on liver and muscle tissues. By the early 1960s, researchers recognized that cAMP enhanced phosphorylase activation without directly interacting with phosphorylase or phosphorylase kinase, suggesting an intermediary kinase in the pathway. In 1968, Donal A. Walsh, John P. Perkins, and Edwin G. Krebs purified a novel protein kinase from rabbit skeletal muscle extracts that exhibited strict dependence on cAMP for activity.^[11] This enzyme, initially termed cAMP-dependent protein kinase, phosphorylated phosphorylase kinase at specific serine residues, thereby activating it and amplifying the hormonal signal in a kinase cascade.^[10] The purification revealed the holoenzyme's dissociation into regulatory and catalytic subunits upon cAMP binding, a mechanism that released the catalytic subunit to phosphorylate diverse substrates beyond just phosphorylase kinase. This breakthrough not only explained cAMP's role in signal transduction but also highlighted PKA as the second protein kinase identified after phosphorylase kinase, marking a pivotal advance in understanding cellular regulation through phosphorylation.^[12] The work by Walsh, Perkins, and Krebs laid the foundation for recognizing PKA's ubiquitous role in eukaryotic cells, influencing subsequent studies on its structure and broader physiological functions.^[10]

Key Developments

Following the discovery of cAMP-dependent protein kinase (PKA) in 1968, early research focused on elucidating its regulatory components. In 1971, a heat-stable protein kinase inhibitor (PKI) was identified as a specific modulator of PKA activity from rabbit skeletal muscle extracts, demonstrating its role in inhibiting the catalytic subunit upon binding. This finding highlighted PKA's susceptibility to endogenous inhibitors, paving the way for studies on fine-tuned regulation. In the late 1970s, PKI was purified from skeletal muscle and other tissues, with early indications of isoforms. Molecular characterization advanced rapidly in the 1980s. The catalytic subunit (C-subunit) of bovine PKA was manually sequenced in 1981 by Shoji et al., marking the first complete amino acid sequence of a eukaryotic protein kinase and revealing conserved motifs like the ATP-binding site, which informed the broader protein kinase superfamily. The complete 75-amino-acid sequence of PKI was determined in 1986 by Scott et al., revealing the pseudosubstrate inhibitory motif (IP20 peptide), first localized in 1985 by Cheng et al. Shortly thereafter, cDNA cloning efforts succeeded; the first cDNA for the mouse PKA C-subunit was isolated in 1986 by Showers and Maurer, enabling recombinant expression and isoform identification, including the alternate Cβ form cloned in 1986. A landmark structural breakthrough occurred in 1991 when Knighton et al. solved the crystal structure of the PKA C-subunit bound to the IP20 peptide at 2.7 Å resolution, unveiling the conserved bilobal architecture of protein kinases with a cleft for ATP and substrate binding.^[13] This structure, the first for any protein kinase, established the "activation loop" mechanism and facilitated rational design of kinase inhibitors. Two years later, in 1993, the ternary complex structure incorporating ATP and two Mg²⁺ ions was resolved by Zheng et al., providing atomic-level insights into phosphoryl transfer and confirming PKA's catalytic precision. Subsequent developments emphasized compartmentalization and dynamics. In 1995, the nuclear export signal (NES) in PKI was identified by Wen et al., explaining its shuttling of the C-subunit out of the nucleus to prevent nonspecific phosphorylation. The concept of A-kinase anchoring proteins (AKAPs) emerged from observations in the early 1980s, with the first evidence of PKA tethering to microtubules reported in 1982 by Theurkauf and Vallee; by the early 1990s, Scott et al. formalized AKAPs as scaffolds localizing PKA to specific subcellular sites, enhancing signal specificity. In 2002, Manning et al.'s kinome analysis built on PKA's foundational data to map over 500 human kinases, underscoring PKA's prototypical role. More recently, in 2020, NMR studies by Olivieri et al. captured the dynamic conformational changes of full-length PKI, revealing allosteric transitions critical for inhibition.^[14] Building on these insights, recent studies as of 2025, including NMR analyses of PKA allosteric networks, continue to refine our understanding of its regulatory dynamics.^[15] These advances have solidified PKA as a model for kinase signaling and therapeutic targeting.

Structure

Subunit Composition

Protein kinase A (PKA), also known as cAMP-dependent protein kinase, exists in an inactive state as a tetrameric holoenzyme composed of two regulatory (R) subunits and two catalytic (C) subunits, forming an R₂C₂ complex. This quaternary structure maintains the catalytic subunits in an inhibited conformation until activation by cyclic AMP (cAMP). The regulatory subunits dimerize via their N-terminal domains, creating binding sites for the catalytic subunits, which are symmetrically bound to each R monomer.^[16]^[17] The regulatory subunits are encoded by four genes, resulting in two main types—type I (RI) and type II (RII)—each with α and β isoforms: RIα (PRKAR1A), RIβ (PRKAR1B), RIIα (PRKAR2A), and RIIβ (PRKAR2B). These isoforms share a conserved modular architecture, including an N-terminal dimerization/docking (D/D) domain that facilitates homodimerization and anchoring to A-kinase anchoring proteins (AKAPs), an autoinhibitory sequence that mimics a substrate to block the catalytic active site, and two tandem cAMP-binding domains (CNB-A and CNB-B) that undergo conformational changes upon ligand binding. Type I isoforms exhibit higher cAMP affinity and are predominantly cytoplasmic, while type II isoforms are often targeted to cellular compartments via AKAPs and feature an additional phosphorylatable serine in the linker region, enabling autophosphorylation that modulates activity.^[16]^[18] The catalytic subunits are derived from three genes: PRKACA encoding Cα, PRKACB encoding Cβ, and PRKACG encoding Cγ, with multiple splice variants increasing isoform diversity. Cα1 and Cβ1 are the most ubiquitous and share a conserved bilobal kinase domain with an N-terminal lobe for ATP binding, a C-terminal lobe for substrate recognition, and an activation loop that becomes phosphorylated for full activity. Alternative splicing produces tissue-specific variants, such as Cα2 (sperm-restricted), Cβ2–Cβ4 (neuronal and immune cell-enriched), and Cγ (testis-predominant), which differ primarily in their N-terminal regions but retain core catalytic function. In the holoenzyme, each C subunit is bound non-covalently to an R subunit via two interaction sites on the R's cAMP-binding domains, ensuring coordinated release upon cAMP elevation.^[19]^[20]

Domain Organization

The catalytic subunit (C) of protein kinase A (PKA) exhibits a conserved bilobal architecture characteristic of eukaryotic protein kinases, consisting of an N-terminal small lobe and a C-terminal large lobe connected by a flexible hinge region. The small lobe, comprising approximately residues 40–120 in the bovine ortholog, is primarily β-sheet rich with five antiparallel β-strands and includes an α-helical segment (αC helix) that plays a key role in ATP binding and orientation. The large lobe, spanning residues 121–280 and a C-terminal tail beyond, is predominantly α-helical and houses the substrate-binding site, with the catalytic cleft formed at the interface between the two lobes to facilitate phosphoryl transfer from ATP to protein substrates. This bilobal structure was first elucidated at 2.7 Å resolution in complex with a peptide inhibitor, revealing conserved motifs such as the glycine-rich loop (G-loop) in the small lobe for ATP phosphate coordination and the activation loop (residues 182–198) in the large lobe that adopts an open conformation in the active state, enabling substrate access.^[21] The regulatory subunits (R), which exist as dimers in the holoenzyme, possess a modular domain organization that enables cAMP-mediated allosteric regulation and inhibition of the catalytic subunits. Each R subunit includes an N-terminal dimerization/docking (D/D) domain (approximately residues 1–61 in RIα), which forms an antiparallel four-helix bundle to mediate R subunit dimerization and anchoring to A-kinase anchoring proteins (AKAPs); an autoinhibitory sequence (AIS) within a flexible linker region (residues 62–133 in RIα) that mimics substrate peptides to block the catalytic cleft; and two tandem cyclic nucleotide-binding (CNB) domains at the C-terminus—CNB-A (residues 134–259) and CNB-B (residues 260–381)—each featuring a conserved β-barrel fold with eight β-strands that bind cAMP cooperatively, inducing conformational changes to release the C subunits. This domain arrangement is conserved across RI and RII isoforms, though RII variants include an additional N-terminal myristoylation site for membrane targeting. Crystal structures of RIα fragments have confirmed the D/D domain's role in stable dimerization and the CNB domains' phosphate-binding pockets, which involve hydrogen bonding networks with the ribose and cyclic phosphate of cAMP.^[22]^[23] In the inactive R2C2 holoenzyme, the AIS from each R subunit inserts into the active site cleft of a C subunit, while the CNB domains remain in a low-affinity conformation for cAMP; upon binding two cAMP molecules per CNB domain, the R subunits undergo a large-scale rearrangement, dissociating from C and exposing the catalytic sites. This organization underscores PKA's role as an allosteric switch, with the D/D domain ensuring spatial localization and the CNB domains providing cooperative sensitivity to cAMP levels.^[24]

Mechanism of Action

Activation Process

Protein kinase A (PKA), also known as cAMP-dependent protein kinase, exists in an inactive holoenzyme form composed of two regulatory (R) subunits and two catalytic (C) subunits, denoted as R₂C₂.^[7] In this tetrameric complex, the R subunits inhibit the kinase activity of the C subunits by occupying their substrate-binding sites and ATP-binding cleft, preventing phosphorylation of target proteins.^[25] Activation of PKA is primarily triggered by the second messenger cyclic adenosine monophosphate (cAMP), which is produced in response to extracellular signals such as hormones binding to G protein-coupled receptors.^[7] The activation process begins with the binding of cAMP to the R subunits, which occurs in a cooperative and ordered manner. Each R subunit contains two distinct cAMP-binding domains: the B domain (also called the fast or high-affinity site) and the A domain (slow or low-affinity site). cAMP first binds to the B domain with high affinity, inducing a conformational change that disrupts inhibitory interactions between the R and C subunits. This is followed by binding to the A domain, which further stabilizes the open conformation of the R subunit and promotes complete dissociation of the holoenzyme.^[25] Structural studies of the type Iα PKA holoenzyme reveal that in the inactive state, a salt bridge between Glu²⁶¹ in the B domain and Arg³⁶⁶ in the A domain tethers capping helices, blocking the cAMP-binding sites; cAMP binding to the B domain severs this bridge, releasing the A domain for subsequent cAMP occupancy and facilitating C subunit liberation.^[25] The released monomeric C subunits are then active and capable of phosphorylating serine/threonine residues on downstream substrates, provided Mg²⁺-ATP is available.^[7] PKA exists in two major isoforms, type I (PKA-I) and type II (PKA-II), which differ in their R subunits (RI and RII) and exhibit distinct activation kinetics and subcellular localizations, though the core cAMP-dependent dissociation mechanism is conserved. PKA-I, with its RI subunits, shows higher cAMP sensitivity (EC₅₀ ≈ 100–370 nM) and is predominantly cytosolic, while PKA-II, anchored via RII's N-terminal amphipathic helix to A-kinase anchoring proteins (AKAPs), requires higher cAMP concentrations (EC₅₀ ≈ 1–10 μM) for activation and is often localized to specific cellular compartments.^[7] In PKA-II, recent findings indicate that autophosphorylation of the RII subunit at Ser⁹⁵ (in RIIα) occurs in the resting holoenzyme state, loosening the RII-C interface without full dissociation; cAMP binding then enhances kinase activity by further altering this interface, allowing substrate access while maintaining partial holoenzyme integrity.^[26]^[27] This mechanism contrasts with the more complete dissociation seen in PKA-I and enables localized signaling without widespread C subunit diffusion.^[26] The activation process is tightly regulated to ensure specificity and prevent aberrant signaling. For instance, the ordered cAMP binding in PKA-I creates a kinetic barrier that amplifies responses to cAMP surges, with mutagenesis studies confirming that residues like Trp²⁶⁰ and Tyr³⁷¹ in RIα are critical for this cooperativity, as their disruption reduces cAMP affinity by 4- to 9-fold.^[25] Once activated, the free C subunits can translocate to the nucleus or other sites to phosphorylate targets like CREB (cAMP response element-binding protein), initiating gene expression changes.^[7] Deactivation occurs upon cAMP hydrolysis by phosphodiesterases, allowing R subunit reassociation with C subunits to reform the inactive holoenzyme.^[7]

Catalytic Mechanism

The catalytic mechanism of protein kinase A (PKA) involves the transfer of the γ-phosphate group from ATP to the hydroxyl group of a serine or threonine residue on a substrate protein, a process that requires two magnesium ions (Mg²⁺) for optimal activity. The catalytic subunit (PKAc) forms a ternary complex with MgATP and the substrate peptide, where ATP binds first to the nucleotide-binding cleft between the N- and C-terminal lobes, inducing a conformational closure that positions the substrate for phosphorylation.^[21] This binding is facilitated by conserved motifs, including the glycine-rich loop (G-loop, residues 50–55) that interacts with the ATP phosphates and the catalytic loop (residues 166–172) containing Asp166, which plays a key role in catalysis. The phosphoryl transfer proceeds via an associative, in-line SN2-like mechanism, where the substrate's hydroxyl oxygen acts as a nucleophile, attacking the electrophilic γ-phosphorus of ATP to form a pentacoordinate transition state.^[28] Asp166 serves as a general base, abstracting the proton from the substrate hydroxyl to enhance its nucleophilicity, while simultaneously coordinating one of the Mg²⁺ ions (the β/γ-Mg²⁺) to stabilize the developing negative charge on the transferring phosphate.^[28] The two Mg²⁺ ions are essential: the α/β-Mg²⁺ bridges the β- and γ-phosphates and interacts with the G-loop backbone, while the β/γ-Mg²⁺, along with Lys168 and other residues, neutralizes the trianionic ATP and positions it for transfer.^[29] Quantum mechanics/molecular mechanics (QM/MM) simulations confirm that this proton abstraction by Asp166 lowers the activation barrier, with the reaction exhibiting partial dissociative character in the transition state, resembling a metaphosphate intermediate.^[28] Following phosphoryl transfer, the products—ADP and the phosphorylated substrate—are released, with ADP dissociation being the rate-limiting step under physiological conditions (k_cat ≈ 10–100 s⁻¹, depending on the substrate). Conformational dynamics, including opening of the lobes and fluctuations in the G-loop, facilitate product egress and reset the enzyme for the next cycle.^[30] This mechanism ensures specificity and efficiency, with substrate recognition primarily driven by interactions at the P+1 and P-2 positions relative to the phosphoacceptor residue.^[30]

Inactivation and Regulation

Inactivation of protein kinase A (PKA) primarily occurs through the reassociation of its regulatory (R) subunits with the catalytic (C) subunits upon a decrease in intracellular cAMP levels. The inactive holoenzyme, a tetramer composed of two R subunits and two C subunits (R₂C₂), forms when cAMP dissociates from the cyclic nucleotide-binding (CNB) domains of the R subunits, allowing the inhibitory segments of the R subunits to rebind and occlude the active site of the C subunits. This process is isoform-specific: type I PKA (with RIα or RIβ) relies on pseudosubstrate inhibition where the R subunit mimics a substrate without being phosphorylated, while type II PKA (with RIIα or RIIβ) involves autophosphorylation of the R subunit at a P-site, which facilitates tighter binding to the C subunit after cAMP release.^[22] Regulation of PKA activity is multifaceted, involving spatial compartmentalization, inhibitory proteins, and counteracting phosphatases to ensure precise signal transduction. A-kinase anchoring proteins (AKAPs) play a central role by binding the RII subunits via their dimerization/docking (D/D) domain, tethering the holoenzyme to specific subcellular locations such as organelles or cytoskeletal elements, thereby restricting C subunit access to substrates and preventing nonspecific phosphorylation upon activation. Additionally, the protein kinase inhibitor (PKI) serves as a potent, high-affinity pseudosubstrate that sequesters free C subunits with sub-nanomolar affinity, often requiring ATP and Mg²⁺ for stable binding, and facilitates nuclear export of the C subunit to terminate signaling in the nucleus.^[22]^[31] Further regulation occurs through post-translational modifications and enzymatic reversal. The C subunit requires phosphorylation at Thr197 in the activation loop for full activity, which is maintained by intrinsic resistance to phosphatases, but can be modulated by protein phosphatase 2A (PP2A) under certain conditions, such as redox stress, leading to dephosphorylation and reduced catalytic efficiency. For type II PKA, autophosphorylation of the RII subunit at Ser95 (in RIIα) enhances reassociation kinetics after cAMP dissociation, providing a feedback loop for rapid inactivation. Redox modifications, including oxidation of conserved cysteines like Cys199 in the C subunit, form disulfide bonds that inhibit activity, offering an additional layer of control in oxidative environments. Phosphatases such as PP2A and calcineurin also dephosphorylate PKA substrates, terminating downstream signaling, and are often co-anchored by AKAPs to coordinate activation and deactivation locally.^[22]^[5]

Functions

Role in Signal Transduction

Protein kinase A (PKA), also known as cAMP-dependent protein kinase, serves as a central mediator in cAMP-mediated signal transduction pathways, converting extracellular signals into intracellular responses through targeted protein phosphorylation. Upon binding of ligands such as hormones (e.g., epinephrine) or neurotransmitters to G protein-coupled receptors (GPCRs), adenylate cyclase is activated to produce cyclic AMP (cAMP) from ATP. Elevated cAMP levels bind to the regulatory subunits of PKA, releasing the active catalytic subunits that phosphorylate serine/threonine residues on substrate proteins, thereby modulating their activity, localization, or interactions.^[32]^[33] In metabolic regulation, PKA transduces signals to control energy homeostasis; for instance, in hepatocytes and muscle cells, it phosphorylates phosphorylase kinase and glycogen synthase, promoting glycogen breakdown and inhibiting synthesis in response to glucagon or adrenaline, which is critical for rapid glucose mobilization during stress. Similarly, in adipocytes, PKA phosphorylates hormone-sensitive lipase, facilitating lipolysis and fatty acid release. These actions exemplify PKA's role in integrating hormonal signals with metabolic adaptation, ensuring cellular energy demands are met efficiently.^[32]^[33] PKA also plays a pivotal role in gene expression and cellular growth by phosphorylating transcription factors such as CREB (cAMP response element-binding protein) at Ser133, enabling recruitment of coactivators like CBP/p300 and activation of cAMP-responsive genes involved in processes like cell survival and differentiation. In neuronal signal transduction, PKA modulates ion channels (e.g., phosphorylation of voltage-gated calcium channels) and synaptic plasticity, contributing to learning and memory formation. In cardiac myocytes, PKA phosphorylates L-type calcium channels and phospholamban, enhancing contractility in response to β-adrenergic stimulation. Spatial specificity in these pathways is achieved through A-kinase anchoring proteins (AKAPs), which tether PKA near substrates, preventing indiscriminate signaling and allowing compartmentalized responses.^[34]^[35]^[36] Furthermore, PKA integrates cAMP signals with other pathways, such as cross-talk with MAPK/ERK cascades via phosphorylation of RAF kinase or inhibition of phospholipase C-β, influencing proliferation and inflammation. In immune cells, for example, PKA suppresses pro-inflammatory cytokine production by phosphorylating NF-κB components, thereby fine-tuning immune responses to prevent excessive activation. This multifaceted role underscores PKA's versatility as a signal transducer across diverse physiological contexts.^[37]^[38]

Tissue-Specific Effects

Protein kinase A (PKA) exhibits diverse tissue-specific effects mediated by its isoform expression patterns and compartmentalized signaling, which tailor cAMP responses to physiological demands in various organs. In adipose tissue, PKA primarily regulates lipolysis and thermogenesis; activation phosphorylates hormone-sensitive lipase (HSL) at Ser563, Ser659, and Ser660, and adipose triglyceride lipase (ATGL) at Ser406, promoting fat breakdown during fasting. The RIIβ regulatory subunit is highly expressed here, and its knockout in mice confers resistance to diet-induced obesity by enhancing energy expenditure and reducing fat accumulation, with fat pad weights halved compared to wild-type controls.^[39] In brown adipose tissue, PKA upregulates uncoupling protein 1 (UCP1) to drive non-shivering thermogenesis, a process impaired in obesity where PRKAR2B mRNA levels are decreased.^[39] In the liver, PKA modulates gluconeogenesis and lipid metabolism through phosphorylation of transcription factors like CREB-regulated transcription coactivator 2 (CRTC2) and CREB-H (CREBH). RIIα is predominant, and its deficiency reduces hepatic steatosis in high-fat diet models by decreasing hepatic PKA activity, with quantitative reductions in triglyceride content observed in RIIα knockout livers. PKA also activates peroxisome proliferator-activated receptor α (PPARα) to enhance fatty acid oxidation, maintaining glucose homeostasis during fasting.^[39] These effects underscore PKA's role in preventing hepatic lipid overload.^[39] Cardiac tissue relies on PKA for excitation-contraction coupling and chronotropy. In cardiomyocytes, PKA phosphorylates phospholamban (PLN) at Ser16, relieving inhibition of sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA2a) to accelerate Ca²⁺ reuptake and enhance relaxation (lusitropy). It also targets L-type Ca²⁺ channels (Ca_v1.2) at Ser1700 for increased Ca²⁺ influx, boosting contractility (inotropy), and myosin-binding protein C (cMyBP-C) at Ser273, Ser282, and Ser302 to optimize cross-bridge cycling. In sinoatrial node cells, PKA-driven PLN phosphorylation elevates heart rate by facilitating sarcoplasmic reticulum Ca²⁺ release. These actions are β-adrenergic receptor-mediated, ensuring adaptive responses to stress, though dysregulation contributes to arrhythmias.^[40] In skeletal muscle, PKA stimulates lipolysis via HSL phosphorylation, but this is blunted in obesity, leading to ectopic lipid accumulation and insulin resistance. PKA also influences glucose uptake indirectly through cAMP crosstalk with insulin signaling.^[39] In the brain, particularly the hippocampus and hypothalamus, PKA drives synaptic plasticity and energy homeostasis. Hippocampal PKA mediates late-phase long-term potentiation (L-LTP) by phosphorylating CREB at Ser133, essential for spatial memory consolidation; inhibitory RIα expression disrupts this, impairing learning in mouse models. In hypothalamic neurons, RIIβ modulates neuropeptide Y (NPY)/agouti-related peptide (AgRP) and pro-opiomelanocortin (POMC) pathways, enhancing leptin sensitivity and thermogenesis in knockouts. Brain-specific catalytic isoforms like Cβ3 and Cβ4, enriched in the dentate gyrus and thalamus, support neuronal development and dopamine synthesis.^[41]^[39] Endocrine tissues highlight PKA's regulatory precision. In pancreatic β-cells, PKA phosphorylates snapin to potentiate insulin secretion via voltage-gated Ca²⁺ channel modulation, a process disrupted in type 2 diabetes. In adrenal cortex, tissue-specific pluripotential cells rely on PKA for steroidogenesis and proliferation, with isoform imbalances linked to tumorigenesis. In bone, PKA promotes osteogenic differentiation of osteoprogenitors by activating RUNX2 and inhibiting adipogenesis, though effects vary by context, supporting bone formation under mechanical stress.^[39]^[42] Overall, AKAP-mediated anchoring ensures these localized effects, preventing off-target signaling and enabling tissue-adapted responses to cAMP elevation.^[43]

Clinical and Research Aspects

Involvement in Diseases

Protein Kinase A (PKA) dysregulation contributes to a variety of diseases through its central role in cAMP-mediated signaling, affecting cellular processes such as proliferation, differentiation, and metabolism. Genetic mutations in PKA subunits directly cause several monogenic disorders, while altered PKA activity is implicated in polygenic and sporadic conditions across multiple organ systems.^[44] In endocrine disorders, inactivating mutations in the PRKAR1A gene, encoding the RIα regulatory subunit, lead to Carney complex, characterized by cardiac myxomas, pigmented skin lesions, and endocrine tumors such as primary pigmented nodular adrenocortical disease causing Cushing's syndrome. These mutations result in haploinsufficiency, elevating PKA activity and promoting tumorigenesis via unchecked cAMP signaling. Activating mutations in PRKACA, encoding the catalytic subunit, cause primary bilateral macronodular adrenal hyperplasia, another form of Cushing's syndrome, by disrupting regulatory interactions and inducing constitutive PKA activation that drives cortisol overproduction. Conversely, certain PRKAR1A mutations impair cAMP binding, reducing PKA activity and causing acrodysostosis, a skeletal dysplasia with hormone resistance, short stature, and occasional intellectual disability.^[44]^[44]^[44] PKA exhibits dual roles in cancer, acting as both oncogenic and tumor-suppressive depending on isoform and context. Overexpression of type I PKA (RIα) promotes proliferation in prostate and lung cancers by enhancing cell cycle progression and survival, while type II PKA (RIIβ) induction inhibits growth in prostate cancer and glioblastoma by triggering differentiation and apoptosis. In Carney complex, PRKAR1A loss drives endocrine tumors, and elevated PKA activity correlates with poor prognosis in adrenocortical carcinomas via increased cAMP-responsive element-binding protein (CREB) phosphorylation. Therapeutic targeting of PKA, such as with site-selective cAMP analogs, has shown potential to revert tumor phenotypes in preclinical models of colorectal and breast cancers.^[45]^[45]^[45] In cardiovascular diseases, aberrant PKA signaling underlies pathological cardiac hypertrophy and heart failure. Excessive PKA activation in response to stress, such as pressure overload, promotes adverse remodeling by enhancing protein synthesis through mTORC1 and ubiquitin-proteasome pathways, leading to fibrosis and contractile dysfunction. Cardiomyocyte-specific PKA inhibition ameliorates hypertrophy and improves survival in mouse models of transverse aortic constriction-induced heart failure. In ischemia-reperfusion injury, heightened PKA activity exacerbates calcium overload and cell death, while reduced PKA contributes to mitochondrial dysfunction in dilated cardiomyopathy.^[46]^[46]^[46] Neurological disorders arise from PKA isoform-specific dysregulation, particularly involving the brain-enriched RIβ subunit. Mutations in PRKAR1B cause Marbach-Shaaf neurodevelopmental syndrome, featuring intellectual disability, autism spectrum disorder, and pain insensitivity due to impaired cAMP-dependent neuronal activation and synaptic plasticity. The PRKAR1B L50R variant is linked to frontotemporal dementia with parkinsonism by disrupting PKA compartmentalization and substrate phosphorylation. In Alzheimer's disease, common PRKAR1B variants associate with late-onset risk, potentially via altered tau phosphorylation and amyloid-beta processing. Acrodysostosis from PRKAR1A mutations can include mild intellectual disability secondary to reduced PKA signaling in the brain.^[41]^[41]^[41] In immune system disorders, dysregulated PKA contributes to autoimmunity and immunodeficiency. Deficiency in lipopolysaccharide-responsive beige-like anchor protein (LRBA), which scaffolds PKA in B cells, underlies common variable immunodeficiency with autoimmune features, as overactive type I PKA inhibits T-cell proliferation and IL-10 production, promoting inflammation. In systemic lupus erythematosus, defective PKA signaling and low cAMP levels lead to T-cell hyperactivation and autoantibody production. PKA activation via phosphodiesterase inhibitors has been explored to restore immune balance in these conditions.^[47]^[47]^[47]

Therapeutic Implications and Recent Advances

Protein kinase A (PKA) has emerged as a promising therapeutic target across multiple disease contexts due to its central role in cAMP-mediated signaling, which regulates cellular processes such as proliferation, metabolism, and stress responses. Dysregulation of PKA contributes to pathologies including skeletal disorders, cardiovascular conditions, neurodegenerative diseases, and cancers, where inhibitors or activators can modulate disease progression. For instance, in fibrous dysplasia (FD), a rare bone disorder characterized by fibrous tissue replacement of normal bone, hyperactive PKA drives lesion formation by promoting osteoclastogenesis and aberrant osteogenesis in skeletal stem cells.^[42] Pharmacological inhibition of PKA using agents like H89 or Rp-8-Br-cAMPs in mouse models significantly improved bone volume fraction, mineral density, and mechanical strength, restoring remodeling balance and halting lesion progression.^[42] These findings underscore PKA's dependency in FD pathogenesis and suggest its inhibition as a viable strategy for human therapy, though clinical translation requires evaluation of long-term safety.^[42] In cardiovascular diseases, PKA acts as a master regulator of both physiological and pathological cardiac hypertrophy (PhCH and PaCH). While PKA supports adaptive growth in PhCH via mTOR-dependent protein synthesis, its hyperactivation in PaCH—triggered by sympathoadrenergic stress or reactive oxygen species—exacerbates adverse remodeling, fibrosis, and heart failure.^[46] Cardiomyocyte-specific PKA inhibition (cPKAi) via gene therapy with rAAV9.PKAi-GFP in transverse aortic constriction (TAC) mouse models ameliorated PaCH, reduced left ventricular mass, improved survival rates, and enhanced cardiac function by suppressing protein synthesis and degradation pathways.^[46] Even in established PaCH, cPKAi reversed hypertrophy and prevented decompensation, positioning it as a potential alternative to β-blockers for treating pressure-overload cardiomyopathies.^[46] Neurodegenerative disorders also highlight PKA's therapeutic potential, particularly through modulation of synaptic plasticity and protein aggregation. In Alzheimer's disease (AD), reduced PKA activity impairs CREB phosphorylation, BDNF expression, and SIRT1 signaling, leading to increased amyloid-β production and synaptic dysfunction.^[48] Enhancing PKA could mitigate these effects by promoting ADAM10 activity and reducing BACE1, though no approved PKA-specific therapies exist yet.^[48] Similarly, in amyotrophic lateral sclerosis (ALS), PKA negatively regulates TDP-43 aggregation; its activation via cAMP analogs in Drosophila models rescued motor neuron defects and extended lifespan, suggesting pathway activation as a strategy to alleviate TDP-43 pathology.^[48] Recent advances in cancer therapy have further illuminated PKA's dual role in cell death and DNA repair, offering opportunities for targeted interventions. PKA intersects with ferroptosis—an iron-dependent cell death pathway—by phosphorylating regulators of lipid peroxidation and antioxidant defenses, exerting context-dependent pro- or anti-ferroptotic effects in tumors.^[49] Inhibition of PKA with compounds like H89 sensitizes cancer cells to ferroptosis inducers, enhancing efficacy when combined with radiotherapy, chemotherapy, or immunotherapy to overcome resistance.^[49] In DNA damage response, PKA promotes nonhomologous end-joining (NHEJ) repair by facilitating 53BP1 recruitment and inhibiting resection of double-strand breaks, thereby reducing homologous recombination (HR).^[50] PKA inhibition shifts repair toward HR, potentially increasing tumor vulnerability to PARP inhibitors, while its stimulation could bolster NHEJ to sensitize cells to ionizing radiation.^[50] These 2025 studies emphasize PKA modulators' versatility in precision oncology, with ongoing preclinical validation paving the way for clinical trials.^[49]^[50]

References

[1]
Protein Kinase A
Protein kinase A is an enzyme that adds phosphate groups to proteins, regulated by cyclic AMP, and is the end effector for hormones using cyclic AMP.
[2]
Protein kinase A catalytic subunit isoform PRKACA - NIH
AGC kinases regulate a multitude of cellular processes including glucose metabolism, cell division and development, the stress responses and molecular aspects ...Protein Kinase A Catalytic... · 3. Prkaca · 5. Prkaca And Disease
[3]
Protein kinase A (PKA) family | Enzymes
PKA, or cyclic AMP-dependent protein kinase, is a heterotetrameric enzyme involved in cyclic AMP-mediated signaling.Missing: definition | Show results with:definition
[4]
The Tails of Protein Kinase A - PMC
Protein kinase A (PKA) is a holoenzyme consisting of a regulatory (R)-subunit dimer and two catalytic (C)-subunits. There are two major families of ...
[5]
Redox Regulation of cAMP-Dependent Protein Kinase and Its Role ...
1. Introduction · 2. The cAMP-Dependent Protein Kinase (PKA) · 3. PKA-C Isoforms · 4. Activation of PKA · 5. PKA in Disease · 6. Reactive Oxygen Species and Redox- ...
[6]
https://doi.org/10.3390/life15040655
[7]
Signaling through cAMP and cAMP-dependent Protein Kinase
The catalytic subunit of cAMP-dependent protein kinase has served as a prototype for the protein kinase superfamily for many years.
[8]
https://doi.org/10.1016/j.cell.2007.07.018
[9]
https://doi.org/10.1038/ng.2956
[10]
https://www.jbc.org/article/S0021-9258(20)59459-3/fulltext
[11]
History of the Protein Kinase Inhibitor and PKA - PubMed Central - NIH
The PKA C-subunit, the second protein kinase to be identified, was discovered by Fischer and Krebs as a contaminant of the PhosK prep because it phosphorylated ...
[12]
Crystal structure of the catalytic subunit of cyclic adenosine ...
Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science. 1991 Jul 26;253(5018):407-14.
[13]
https://pubmed.ncbi.nlm.nih.gov/1862342/
[14]
R-subunit Isoform Specificity in Protein Kinase A - NIH
In the absence of cAMP, PKA exists in an inactive state as a tetrameric holoenzyme composed of a homodimeric regulatory (R) subunit and two catalytic (C) ...
[15]
Localization and quaternary structure of the PKA RIβ holoenzyme
The inactive PKA holoenzyme is composed of a regulatory (R) subunit dimer and two catalytic (C) subunits. Binding of cAMP to the R-subunits unleashes the C- ...Results · Pka Riβ Subunit Is Enriched... · Based On Saxs, Riα And Riβ...
[16]
The Molecular Basis for Specificity at the Level of the Protein Kinase ...
PKA is a tetrameric holoenzyme consisting of a regulatory (R) subunit dimer and two catalytic (C) subunits. The R subunit is the receptor for cAMP and ...Abstract · Catalytic Subunit Structural... · Conserved Heterogeneity in...
[17]
PKA Cβ: a forgotten catalytic subunit of cAMP-dependent protein ...
With the discovery of a second protein kinase (PK), cAMP-dependent protein kinase (PKA) in 1968 [2] came the appreciation that protein kinases may be a larger ...Discovery Of The Pka... · Pathogenic Mutations In Cβ · Expression Of Cα And CβMissing: milestones | Show results with:milestones
[18]
Evolution of the cAMP-dependent protein kinase (PKA) catalytic ...
Jul 25, 2017 · The PKA catalytic subunit gene was duplicated in a common ancestor of all Gnathostomata.
[19]
Crystal Structure of the Catalytic Subunit of Cyclic Adenosine ...
Abstract. The crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase complexed with a 20-amino acid substrate ...
[20]
Assembly of allosteric macromolecular switches: lessons from PKA
The domain organization is conserved in all regulatory subunit isoforms and includes a dimerization and docking domain (D/D domain) located at the N ...
[21]
PKA RIα Homodimer Structure Reveals an Intermolecular Interface ...
(A) Shown is the overall functional domain organization of the full-length RIα construct used in this study. This included the D/D domain, the linker with the ...
[22]
Article PKA-I Holoenzyme Structure Reveals a Mechanism for cAMP ...
Sep 21, 2007 · Top: domain organization of the catalytic and regulatory subunits. The two red spheres indicate the phosphorylation sites Thr197C and Ser338C in ...
[23]
https://www.cell.com/structure/fulltext/S0969-2126%2813%2900406-1
[24]
Protein kinase A activation: Something new under the sun?
May 17, 2018 · Originally purified by Walsh et al. (1968), the cAMP-dependent protein kinase known as PKA increased in prominence when Knighton et al.
[25]
A QM/MM study of Kemptide phosphorylation catalyzed by protein ...
Asp166 is a base catalyst that abstracts the HγSer17 of Kemptide thus facilitating the phosphoryl transfer, but it also acts as an acid catalyst by donating the ...
[26]
https://rupress.org/jcb/article/217/6/1895/39341/Protein-kinase-A-activation-Something-new-under
[27]
https://www.sciencedirect.com/science/article/pii/S0021925819556782
[28]
cAMP-dependent protein kinase (PKA) complexes probed by ...
cAMP-dependent protein kinase (PKA) is an archetypal biological signaling module and a model for understanding the regulation of protein kinases.Experimental · Detection Of Pkac And Pka... · Ion Mobility--Ms And...
[29]
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4373616/
[30]
The Cyclic AMP Pathway - PMC - NIH
PKA-anchoring proteins (AKAPs) provide specificity in cAMP signal transduction by placing PKA close to specific effectors and substrates.
[31]
https://portlandpress.com/biochemj/article/473/19/3159/49635/cAMP-dependent-protein-kinase-PKA-complexes-probed
[32]
https://doi.org/10.1146/annurev.cb.08.110192.002241
[33]
https://pmc.ncbi.nlm.nih.gov/articles/PMC3504441/
[34]
https://doi.org/10.1038/35085068
[35]
The cyclic AMP signaling pathway: Exploring targets for successful ...
This review aimed to provide an understanding of the effects of the cAMP signaling pathway and the associated factors on disease occurrence and development.
[36]
PKA functions in metabolism and resistance to obesity
cAMP/PKA signaling performs numerous functions throughout the CNS and its roles are well-established in the molecular pathways governing fear and fear memory.
[37]
Physiological and pathological roles of protein kinase A in the heart
PKA regulates cardiac performance and morphology, enhancing contractility. Dysregulation of PKA is linked to heart diseases like ischemia and heart failure.
[38]
Protein Kinase A in neurological disorders
Mar 13, 2024 · This review highlights distinct isoform-specific cognitive deficits that occur in both PKA catalytic and regulatory subunits, and how tissue- ...
[39]
Protein kinase A is a dependent factor and therapeutic target in ...
Jul 1, 2025 · PKA promotes osteoclastogenesis, induces aberrant osteogenic differentiation and proliferation of SSCs, but suppresses bone formation, leading ...
[40]
cAMP/PKA signaling defects in tumors: genetics and tissue-specific ...
A major discovery was the identification of tissue-specific pluripotential cells (TSPCs) as the culprit behind tumor formation not only in the adrenal, but ...
[41]
[PDF] Gas–Protein Kinase A (PKA) Pathway Signalopathies - Gutkind Lab
Mar 7, 2024 · PKA facilitates the transfer of the gamma phosphate of ATP to serine or threonine residues preferentially in the context of the consensus Arg- ...Missing: milestones | Show results with:milestones
[42]
Protein Kinase A in Cancer - PMC - NIH
PKA may represent a biomarker for tumor detection, identification and staging, and may be a potential target for pharmacological treatment of tumors.
[43]
Protein Kinase A Is a Master Regulator of Physiological and ...
Jan 26, 2024 · Cardiomyocyte PKA plays an essential role in both physiological and pathological cardiac growth/hypertrophy by regulating both protein synthesis ...
[44]
Role of Protein Kinase A Activation in the Immune System ... - MDPI
Feb 4, 2023 · This review summarizes the functions of PKA in immunity and provides the most recent information regarding LRBA deficiency to deepen our understanding of ...<|control11|><|separator|>
[45]
Protein kinases in neurodegenerative diseases - Nature
May 7, 2025 · Role of protein kinase A in regulating mitochondrial function and neuronal development: implications to neurodegenerative diseases. Rev.
[46]
https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.123.322729
[47]
PKA prevents the resection of DNA double-strand breaks and favours nonhomologous end-joining - Scientific Reports
### Summary of Findings on PKA's Role in DNA Damage Repair and Implications for Cancer Therapy